<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004429</url>
  </required_header>
  <id_info>
    <org_study_id>SynAct-CS002</org_study_id>
    <nct_id>NCT04004429</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease</brief_title>
  <acronym>SynAct-CS002</acronym>
  <official_title>A Double-blind, Multicenter, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients With Active Joint Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SynAct Pharma Aps</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SynAct Pharma Aps</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study&#xD;
      with repeated doses of AP1189. The study population will consist of newly diagnosed subjects&#xD;
      with severe active Rheumatoid Arthritis, defined with a Clinical Disease Activity score&#xD;
      (CDAI) &gt; 22, who are to start up-titration with methotrexate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, two-part, randomized, double-blind, placebo-kontrolled, 4-week study with&#xD;
      repeated doses of AP1189. The study population will consist of newly diagnosed subjects with&#xD;
      severe active Rheumatoid Arthritis, defined with a Clinical Disease Activity score (CDAI) &gt;&#xD;
      22, who are to start up-titration with methotrexate.&#xD;
&#xD;
      The study will be conducted in two parts separated by an interim analysis.&#xD;
&#xD;
      Part 1: The subjects will be randomized in a 1:1:1 ratio into: .&#xD;
&#xD;
        -  AP1189 dose 50 mg&#xD;
&#xD;
        -  AP1189 dose 100 mg&#xD;
&#xD;
        -  placebo&#xD;
&#xD;
      INTERIM ANALYSIS&#xD;
&#xD;
      Part 2: All subjects will be randomized into either design 1, 2 or 3 based on data from the&#xD;
      interim analysis.&#xD;
&#xD;
        -  Design 1: AP1189 dose 50 mg or placebo in a 2:1 ratio&#xD;
&#xD;
        -  Design 2: AP1189 dose 100 mg or placebo in a 2:1 ratio&#xD;
&#xD;
        -  Design 3: Continue with the same doses as in Part 1&#xD;
&#xD;
      The purpose of this study is to determine the safety and efficacy of 2 doses of AP1189&#xD;
      compared with placebo after 4 weeks of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, two-part, randomized, double-blind, placebo-controlled 4-week study with repeated doses of AP1189</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CDAI</measure>
    <time_frame>4 weeks</time_frame>
    <description>The change in CDAI score from severe (CDAI &gt; 22) to moderate (CDAI &lt;= 22) after 4 weeks treatment compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Swollen and tender joints</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of subjects achieving a reduction of more than 10 swollen and/or tender joints compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAI score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of subjects achieving a change in CDAI score compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28 score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of subjects achieving a change in DAS28 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAQ-DI (Health Assessment Questionnaire-Disability Index) questionnaire</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of subjects achieving a change in HAQ-DI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACIT-Fatigue questionnaire</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of subjects achieving a change in FACIT-Fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR (American College of Rheumatology) response</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of subjects achieving a response assessed by ACR20, ACR50 and ACR70</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect of AP1189 as measured on the following biomarkers: CXCL13, IL-1β, IL-6, IL-10, and TNF-α</measure>
    <time_frame>4 weeks</time_frame>
    <description>Effect of AP1189, compared to placebo and by treatment group on inflammatory and collagen destructive biomarkers</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>50 mg AP1189</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg AP1189</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg AP1189. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension, i e. the powder will be added 50 ml water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo. The treatment is a 4 week treatment. Each daily dose will be administered as a suspension i e. the powder will be added 50 ml water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg AP1189</intervention_name>
    <description>50 mg AP1189 powder in bottle</description>
    <arm_group_label>50 mg AP1189</arm_group_label>
    <other_name>AP1189</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP1189</intervention_name>
    <description>100 mg AP1189 powder in bottle</description>
    <arm_group_label>100 mg AP1189</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo powder in bottle</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent has been obtained prior to initiating any study specific&#xD;
             procedures&#xD;
&#xD;
          -  Male and female subjects, 18 to 85 years of age&#xD;
&#xD;
          -  Confirmed diagnosis of (RA) Rheumatoid Arthritis according to the 2010 ACR/EULAR RA&#xD;
             classification criteria&#xD;
&#xD;
          -  Polyarthritis with joint swelling and tenderness of a minimum of three joints out of&#xD;
             68 joints tested&#xD;
&#xD;
          -  Candidate for Methotrexate treatment&#xD;
&#xD;
          -  Is about to begin treatment with MTX (Methotrexate)&#xD;
&#xD;
          -  Tested positive for anti-CCP Anti-cyclic citrullinated peptide) or RF (Rheumatoid&#xD;
             Factor)&#xD;
&#xD;
          -  Severe active RA (CDAI &gt; 22) at screening and baseline&#xD;
&#xD;
          -  Negative QFG-IT (QuantiFERON-in-Tube test)&#xD;
&#xD;
          -  Subjects should be able to complete the PRO (Patient Reported Outcome) questionnaires&#xD;
&#xD;
          -  Females of child-bearing potential may only participate if using reliable means of&#xD;
             contraception or are post-menopausal. Surgically sterilized women at least 6 months&#xD;
             prior to screening&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test at screening and&#xD;
             baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any other study involving investigational drug(s) within 4 weeks&#xD;
             prior to study entry&#xD;
&#xD;
          -  Major surgery within 8 weeks prior to screening or planned surgery within 1 month&#xD;
             following randomization&#xD;
&#xD;
          -  Rheumatic autoimmune disease other than RA, including SLE (systemic Lupus&#xD;
             Erythematosus), MCTD (Mixed Connective Tissue Disease), scleroderma, polymyositis, or&#xD;
             significant systemic involvement secondary to RA. Sjögren syndrome with RA is&#xD;
             allowable&#xD;
&#xD;
          -  Functional class IV as defined by the ACR Criteria for Classification of Functional&#xD;
             Status in RA or wheelchair/bedbound&#xD;
&#xD;
          -  Prior history of or current inflammatory joint disease other than RA&#xD;
&#xD;
          -  Subjects with fibromyalgia&#xD;
&#xD;
          -  Initiation or change in dose for NSAIDs within 2 weeks prior to dosing with the IMP&#xD;
             (Investigational Medicinal Product)&#xD;
&#xD;
          -  Corticosteroids are prohibited within 2 weeks prior to screening (and during the&#xD;
             entire treatment period and until the final visit&#xD;
&#xD;
          -  Evidence of serious uncontrolled concomitant cardiovascular, nervous system,&#xD;
             pulmonary, renal, hepatic, endocrine, or gastrointestinal disease&#xD;
&#xD;
          -  Have prior renal transplant, current renal dialysis or severe renal insufficiency&#xD;
             (determined by a derived glomerular filtration rate (GFR) using Cockcroft Gault&#xD;
             Formula of ≤30 mL/min/1,73 m2 calculated by the local lab)&#xD;
&#xD;
          -  Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel disease&#xD;
             where flares are commonly treated with oral or parenteral corticosteroids&#xD;
&#xD;
          -  Evidence of active malignant disease&#xD;
&#xD;
          -  Pregnant women or nursing mothers&#xD;
&#xD;
          -  History of alcohol, drug, or chemical abuse within the 6 months prior to screening&#xD;
&#xD;
          -  Neuropathies or other painful conditions that might interfere with pain evaluation&#xD;
&#xD;
          -  Body weight of &gt;150 kg&#xD;
&#xD;
        Exclusion criteria that only applies for Norway&#xD;
&#xD;
          -  Evidence of moderate and/or severe organ dysfunction&#xD;
&#xD;
          -  Abnormal chest x-ray (as per the discretion of the investigator&#xD;
&#xD;
          -  Evidence of positive hepatitis serology&#xD;
&#xD;
          -  Evidence of peptic ulcer disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen-Margrethe Hauge, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus Universitetshospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Espen A Haavardsholm, Concultant, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diakonhjemmet Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonhjemmet Sykehus</name>
      <address>
        <city>Oslo</city>
        <zip>0370</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

